GuruFocus data shows that Matthew Gall, CFO of ITeos Therapeutics Inc ( NA:ITOS), sold 5,000 shares on December 27, 2021.
Insiders selling shares can cause investors concern. This could indicate that insiders have become bearish about the shares of their company's stock. Investors should pay close attention to insiders' ability to determine the company's value. We will take a closer look at the insider sale to determine if ITeos Therapeutics Inc is worthy of some skeptical investors.
Matthew Gall trades
Matthew Gall sold over 5,000 shares during the last year.
Matthew Gall's recent sale was therefore the last time he sold shares in the past 12 months. They may have changed their minds about the stock after a negative development.
Trends from the inside
One insider selling doesn't necessarily mean other insiders have a bearish view of the stock. Is the stock being sold by other insiders? Or have top company executives and owners bought more recently?
ITeos Therapeutics Inc's insider transactions history shows that there were 1 insider buys over the last year. In the meantime, there were 68 insider sales in that same period.
Matthew Gall isn't the only insider selling shares lately; there are other insiders selling more than buying, which can be troubling for investors. We should remember that insiders can sell shares for many reasons. A high level of insider sales could indicate a negative sign or neutral, depending upon the motivation behind it.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at email@example.com!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
This article first appeared on GuruFocus.